Herbal Dispatch Inc. announced a 115% increase in gross sales to $6.2 million in Q4 2025 compared to Q4 2024, with net revenue rising to $4.1 million. The company achieved positive adjusted EBITDA of $0.1 million in Q4, improving from a loss the previous year, driven by higher sales volumes and better cost efficiency. For the full year 2025, sales grew 37% to $16.5 million, and adjusted EBITDA losses narrowed, reflecting progress toward profitability. Looking ahead, Herbal Dispatch aims to expand its recreational and medical cannabis sales, especially targeting veterans, and increase exports to international markets in 2026.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
